Collar StrategyNVO · USRisk: Very low

Collar Strategy on Novo Nordisk A/S

Complete example: Collar Strategy on Novo Nordisk (NVO) — including strikes, premium, break-even, and interactive payoff diagram.

Market view

Neutral to defensive

Complexity

Intermediate

Sector

Consumer

Typical price

$85,00

Underlying

Novo Nordisk A/S for Options Traders

Novo Nordisk A/S is the Danish pharma giant behind the GLP-1 blockbusters Ozempic and Wegovy, and one of Europe's most valuable companies. US options are accessible via its NYSE-listed ADRs (ticker NVO). News on trials, competition (Eli Lilly) and manufacturing capacity pushes volatility to an elevated level (IV 30-52%) — attractive for premium strategies with clearly defined risk.

Symbol

NVO

Market

IV range

30–52%

Currency

USD

Options note: US ADR options (NYSE); American-style; weekly expirations; solid liquidity for a European pharma name.

Overview

Collar Strategy — Quick Overview

The collar combines an existing stock position with buying a protective put and simultaneously selling an OTM call. The short call partially or fully finances the expensive protective put (zero-cost collar). The result: your downside loss is limited (put protects), but your upside profit is capped (short call). A collar is the strategy of choice for investors who want to protect existing gains in a position.

Advantages

Clearly limited downside loss risk
Often free or cheap to implement (zero-cost collar)
No need to sell the stock position
Dividend rights are maintained (as long as not assigned)

Disadvantages

Upside capped: strong price gains are not captured
More complex than a simple protective put
Early assignment of short call possible with US options (before dividends)
Three positions (stock + put + call) increase management complexity

Example Trade

Collar Strategy on Novo Nordisk

Illustrative example based on a typical Novo Nordisk price of $85,00. Strikes and premiums are indicative — actual market prices will vary.

Position	Type	Strike	Action	Premium
100 Shares (held)	Stock position	$85,00	Long (entry price)	—
Long Put (protection)	Put	$77,50	Buy (debit)	-$1,26
Short Call (finances put)	Call	$92,50	Sell (credit)	+$1,68
Net credit received				+$0,42 ($42 per contract)

Max Profit

$792

per contract

Max Loss

-$708

per contract

Break-even

$84,58

Payoff

Payoff Diagram at Expiration

Profit and loss of the Collar Strategy on Novo Nordisk depending on the price at expiration. Values per contract (100 shares).

Suitability

Why Collar Strategy for Novo Nordisk?

Medium volatility provides enough premiums for attractive collars. You can buy puts with good strikes and sell somewhat more distant calls — preserving upside potential. Particularly after strong rallies (wanting to protect gains) or before uncertain market phases, a collar on this stock is an effective hedging strategy.

When is the right time?

1Protect existing stock gains (e.g., position is significantly up)
2Turbulent market phases or uncertainty before specific events
3Tax optimization: protection without selling the position (controls realization timing)
4Long-term investors seeking temporary hedges
5Hedge equity compensation plans (RSUs, stock options)

Deep Dive

Why Novo Nordisk for Options Traders

Novo Nordisk is one of Europe's most valuable companies and the market leader in GLP-1 drugs (Ozempic, Wegovy). Liquid US options are accessible via its NYSE-listed ADRs (ticker NVO). IV is elevated at typically 30-52%, driven by trial data, competition (Eli Lilly) and manufacturing capacity. For options traders NVO is an underlying with solid premiums and a clear fundamental story — suitable for defined-risk premium strategies.

Historical Context

Novo Nordisk saw an exceptional re-rating in 2021-2023 as Ozempic and Wegovy opened up the obesity market. Sharp pullbacks followed as disappointing trial data (including on next-generation drugs) and growing competitive pressure from Eli Lilly weighed on the valuation. These swings between euphoria and disappointment produce recurring IV spikes around trial results and quarterly reports. Traders should keep the calendar of clinical data and approval decisions in view.

FAQ

FAQ: Collar Strategy on Novo Nordisk

How do I trade Novo Nordisk options as a German investor?

The most liquid route is US options on the NYSE ADRs (ticker NVO), which requires a broker with access to US options markets. These options are American-style with weekly expirations. Alternatively, European derivatives venues list options on the Danish ordinary share, but with lower liquidity. This content is informational, not investment advice.

What drives volatility on Novo Nordisk?

The most important driver is clinical trial data on GLP-1 drugs and their successors, followed by competition with Eli Lilly and manufacturing-capacity news. Both positive and negative surprises often move the stock by double digits. IV rises materially around these dates and collapses afterward — a classic pattern to account for when timing options strategies.

Is NVO suitable for conservative income strategies?

Relatively well, compared with high-volatility momentum names. The elevated but not extreme IV (30-52%) and the fundamental market leadership make covered calls and cash-secured puts sensible. It nonetheless remains a single stock with clinical risk — limit position size and avoid trial/earnings dates. This content is informational only.